Selective depletion of alloreactive T cells from stem-cell allografts should abrogate graft-versus-host disease while preserving beneficial T cell specificities to facilitate engraftment and immune reconstitution. We therefore explored a refined immunomagnetic separation strategy to effectively deplete alloreactive donor lymphocytes expressing the activation antigen CD69 upon stimulation, and examined the retainment of antiviral, antileukemic, and immunoregulatory T cells. In addition to the CD69 high T cell fraction, our studies retrieved two T cell subsets based on residual CD69 expression. Whereas, truly CD69 neg cells were devoid of detectable alloresponses to original stimulators, CD69-low (CD69 low )-expressing T cells elicited significant residual alloreactivity upon restimulation. In interferon-c enzyme linked immunospot assays, anti-cytomegalovirus and anti-Epstein-Barr virus responses were preserved at significant numbers among CD69 neg T lymphocytes. Accordingly, T cells recognizing the leukemia-associated Wilm's tumor-1 antigen were still detectable in the CD69 neg subset. However, antiviral and antileukemic specificities were also consistently found within CD69 low T cells, suggesting that memory-type donor T cells were partially captured due to residual CD69 expression. Finally, CD4 þ CD25 þ Foxp3 þ immunoregulatory T cells did not upregulate CD69 upon allogeneic stimulation. Our data suggest that CD69-mediated removal of alloreactivity can result in efficient allodepletion, but may partially affect the persistence of antiviral and antileukemic donor memory specificities captured among CD69 low -expressing lymphocytes.
Introduction
In allogeneic hematopoietic stem cell transplantation (AHSCT), donor T cells (TCD), either present in the stem cell graft or given as donor lymphocyte infusion (DLI), support engraftment, 1 improve immunity to infectious agents, 2 and exert potent graft-versus-leukemia (GVL) effects, respectively. [3] [4] [5] However, alloreactive TCD are also central mediators of the graft-versus-host disease (GVHD), 6 ,7 which remains the major complication in AHSCT and thus limits its broader application. Nonselective depletion of TCD effectively controls GVHD, but simultaneously increases the risk for opportunistic infections and abolishes therapeutically desired alloreactivity against recurrent leukemia. However, there has been accumulating evidence suggesting that distinct subsets of allogeneic T lymphocytes confer GVL reactivity in the absence of GVHD. [8] [9] [10] Indeed, strong antileukemic reactions can be observed in the absence of GVHD after both AHSCT and DLI. 11 Based on these observations separation and expansion of allogeneic T cells devoid of graftversus-host (GVH) reactivity has been of central interest in AHSCT.
Several conceptually different strategies to selectively deplete alloreactive donor T lymphocytes either ex vivo, for example by photodynamic purging, 12 by CD95-mediated activation-induced apoptosis, 7 or in vivo by inducible 'suicide' genes expressed in genetically modified allogeneic T lymphocytes 13 have been proposed. Alternatively, numerous studies on the selective removal of alloreactive T cells based on their de novo expression of antigens upon activation such as CD25, [14] [15] [16] [17] CD69, 18, 19 or CD4 20 have been reported. Furthermore, CD4 þ CD25 þ regulatory T (T reg ) cells, recently defined as suppressive regulators of immune responses, have been suggested to play an important role in GVHD control. 21 Thus, T reg cells might be of additional importance within the pool of allogeneic T cells retained after selective depletion of alloreactivity. However, the majority of studies published on the selective depletion of alloreactive T cell subsets so far did not include detailed analyses on the persistence of antileukemic and antiviral T cells after the depletion maneuver.
In this study, we used a modified strategy of a previously reported CD69-based immunomagnetic selection protocol 18 to investigate the retainment of sufficient numbers of allogeneic T cells exhibiting antiviral, antileukemic, and immunoregulatory functions after allodepletion. Using responder T cells derived from HLA-A*0201-positive donors, our specificity analyses included known HLA-A*0201-binding cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Wilms tumor-1 (WT1) peptide epitopes.
The results presented herein demonstrate that substantial (X95%) allodepletion could be achieved while significant antiviral and potentially antileukemic T cell specificities were retained in the allodepleted CD69-negative (CD69 neg ) cell population. However, a considerable fraction of TCD reactive against CMV, EBV and WT1 epitopes appeared to be trapped in a subset composed of CD69-low (CD69 low )-expressing T cells with residual alloreactivity. Furthermore, CD4
þ CD25 þ Foxp3 þ T reg cells did not upregulate CD69 after allogeneic stimulation, and, thus, should not be affected by the CD69-based depletion procedure. Taken together, our results suggest that stringent allodepletion via CD69 results in highly efficient and selective removal of alloreactivity but may influence the recovery of desired antileukemic and antiviral T cell specificities.
Materials and methods

Peptides
Peptides used herein were EBV BMLF1 peptide 280-288 (GLCTLVAML), CMV pp65 peptide 495-503 (NLVPMVATV), and human WT1 peptides 126-134 (RMFPNAPYL) and 301-310 (RVPGVAPTL). They were synthesized on solid phase using Fmoc chemistry, purified by reversed-phase high-performance liquid chromatography, and characterized by mass spectrometry.
Cell lines
The human mutant cell line T2 (174 Â CEM.T2) 22 and the human CML cell line K562 transfected with full-length cDNA encoding the HLA-A*0201 allele, 23 were cultured in RPMI 1640 medium (Cambrex Bio Science, Verviers, Belgium) supplemented with L-glutamine (2 mM/l), penicillin (100 U/ml), streptomycin (100 mg/ml) (Gibco BRL, Grand Island, NY, USA) and 10% FCS (Cambrex Bio Science). Cell cultures were kept in a water-saturated atmosphere with 5% CO 2 at 371C.
Isolation of primary CD3
þ T cells from peripheral blood mononuclear cells (PBMC) PBMC were obtained from buffy coat preparations of HLA-A*0201-positive healthy donors by Ficoll-Paque (Biochrom AG, Berlin, Germany) density gradient centrifugation. CD3 þ T cells were negatively isolated by immunomagnetic separation using a pan T cell isolation kit according to the manufacturer's instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). Purity of the enriched T cells always exceeded 98% as determined by flow cytometry.
For additional experiments, PBMC kept frozen in serumfree X-VIVO 20 medium (Cambrex Bio Science) containing 10% DMSO were rapidly thawed at 371C, washed in X-VIVO 20 medium and used for culture as described below.
Stimulation and depletion of alloreactive T cells based on CD69 expression
Freshly isolated or thawed untouched CD3 þ T cells were stimulated with irradiated (30 Gy) PBMC from different donors in allogeneic mixed lymphocyte cultures (MLC) at responder/stimulator ratios of 1:2-1:3, respectively, for 72 h in serum-free X-VIVO 20 medium. Cultured cells were then harvested, washed, and stained with anti-CD69-phycoerythrin (PE) antibody (Immunotech, Marseille, France; 20 ml/10 7 cells in 80 ml MACS buffer composed of PBS, 2 mM EDTA and 0.5% human serum albumine) at 6-121C for 10 min. Following incubation with anti-PE microbeads (20 ml/10 7 cells in 80 ml MACS buffer) at 6-121C for 15 min, excess beads were removed, and the cell suspension was passed through a prewashed LD-depletion column (Miltenyi) according to the manufacturer's instructions. The cell suspension running through the matrix was collected as the CD69 neg subset. Subsequently, the column was washed twice with 1 ml buffer and the effluent was collected separately to be further examined as the CD69 low subset. For isolation of the CD69-high (CD69 high ) fraction, the column was removed from the separator and cells were flushed out with 3 ml of buffer using a plunger.
To determine the depletion efficiency, samples of CD69 neg , CD69 low and CD69 high fractions were analyzed by flow cytometry. 
Immunophenotyping
Expression of cell surface antigens was examined using the following murine anti-human monoclonal antibodies (mAb) and corresponding isotype-matched control mAb in direct immunofluorescence staining: anti-CD3-FITC, anti-CD3-PE, anti-CD4-FITC, anti-CD4-PE, anti-CD69-PE (all from Immunotech, Marseille, France) and anti-CD25-PE (Miltenyi). Briefly, 1 Â 10 5 viable cells were incubated with mAb for 15 min at 41C followed by two washings with PBS containing 0.5% FCS.
Expression analyses of CD69 on CD4
þ CD25 þ Foxp3 þ T reg cells was performed using a regulatory T cell staining kit (NatuTec, Frankfurt/Main, Germany) according to the manufacturer's instructions. Briefly, PBMC were first surface labeled with CD4-PE or CD25-APC mAb, respectively, followed by fixation and permeabilization. After blocking with 2% rat serum, cells were counterstained with anti-human Foxp3-FITC mAb (clone PCH101). For all flow cytometry analyses, 10 000 events were collected after gating of viable lymphocytes by FSC and SSC signal list mode data in Cellquest Pro software on a FACS-Calibur instrument (Becton Dickinson, Heidelberg, Germany).
Interferon-g (IFN-g) enzyme-linked immunospot (ELISpot) assay
MultiScreen-MAHA S45 plates (Millipore, Eschborn, Germany) were coated with 10 mg/ml of anti-human IFN-g mAb (clone 1-D1K; Mabtech, Stockholm, Sweden) in PBS overnight at 41C. After unbound antibody was removed by extensive washings with PBS, T cell responders (10 5 /well) and K562-HLA-A*0201 transfectants or T2 cells, respectively, used as stimulators (10 5 /well) were seeded in ELISpot plates in triplicates in serum-free X-VIVO 20 medium. Peptides were added at final concentration of 10-20 mg/ml directly into the wells or were loaded onto stimulator cells for 2 h prior to addition of T cells. As controls, T cells were incubated in medium alone as well as with stimulators without peptide. After a culture period of 20 h at 371C, plates were extensively washed with PBS/ Tween 20 (0.05%) to remove cells. IFN-g spots were detected at sites of secretion with biotinylated anti-human IFN-g mAb (clone 7-B6-1-biotin; Mabtech, Stockholm, Sweden) at 2 mg/ml in PBS/BSA (0.5%) for 2 h. Plates were washed again, and were subsequently incubated with avidin-peroxidase complex (1/100; Vectastain Elite Kit; Vector, Burlinggame, CA, USA) for 1 h at room temperature. Unbound complex was removed by successive washings with PBS/Tween 20 (0.05%) and with PBS alone.
Peroxidase staining was performed with 3-amino-9-ethylcarbazole (Sigma, Deisenhofen, Germany) for 4 min and stopped with running tap water. Spots were analyzed using an Axioplan 2 microscope (Carl Zeiss, Jena, Germany) and the computer-assisted image analysis program KS ELISpot 4.1 (Carl Zeiss Vision, Hallbergmoos, Germany). Results represent means of triplicates, and s.d. are given.
Results
Alloreactive T cells are selectively depleted via CD69
We modified a previously published CD69 immunomagnetic separation protocol 18 to selectively eliminate human alloreactive T cells in HLA mismatch donor-recipient pairs. Purified CD3 þ T cells derived from PBMC of HLA-A*0201-positive healthy donors were cocultured with allogeneic irradiated recipient PBMC at a ratio of 1:2-1:3 in bulk MLC for 72 h. Following activation of alloreactive responder cells, the expression of the CD69 activation antigen increased with a mean of 8.675.3% above basal CD69 levels determined on freshly isolated T cells (Table 1) . Efficient depletion of activated CD69 pos T cells was then achieved by labeling the responder cell population with monoclonal anti-CD69-PE antibody followed by incubation with anti-PE magnetic beads and magnetic cell sorting using LD depletion columns.
As shown for a representative experiment (Figure 1 ), this protocol resulted in a first effluent of the column containing cells devoid of CD69 expression and, thus, was defined as the CD69 neg subset. We collected an additional fraction of cells passing the column during the washing procedure which expressed low amounts of CD69 and was termed as the CD69 low subset. Finally, we eluted the CD69 high subset consisting of alloreactive T cells expressing high levels of this activation marker (Figure 1) . By comparing the numbers of CD69 pos cells prior to separation with numbers of residual CD69 pos cells detected in the CD69 neg and CD69 low subsets after separation, the immunomagnetic Following stimulation of purified CD3 + T cells with allogeneic irradiated PBMC for 72 h, activated alloreactive specificities were depleted by magnetic cell separation via CD69. To determine cell purity and cell depletion efficiency, CD69 expression was analyzed in the different subsets obtained after depletion by flow cytometry. Results from nine independent donor-recipient pairs tested are listed. a CD69 expression before separation represents the increase in CD69 expression above baseline levels on CD3 + T cells after 72 h of allogeneic mixed lymphocyte cultures (MLC).
sorting on LD columns resulted in a mean depletion efficiency of 95.572.5% (range, 92.0-98.4%) for the subset of CD69 neg cells, and 88.277.4% (range, 74.0-97.6%) for the population of CD69 low cells (Table 1 ). The mean cell purity of the CD69 neg and CD69 low subsets calculated as 100% -CD69 pos cells in the obtained fractions was X98% for the CD69 neg subset (range, 98-99%) and X97% (range, 94-99%) for the CD69 low subset (calculated from Table 1 ). In addition, the mean cell yield of all experiments performed (n ¼ 9) was 25% (range, 10-41%) for the CD69 neg fraction and 57% (range, 39-71%) for the CD69 low fraction. Not surprisingly, since the columns used were designed for depletion strategies, the enrichment process was less stringent for the CD69 high subset ranging from 20 to 55% (mean 34.1710.8%) of alloreactive CD69 þ responder cells (Table 1) .
Depletion of alloreactive T cells via CD69 is efficient and specific for the stimulating alloantigens Following CD69-mediated depletion of alloreactive MLC responders, CD69 pos T cells remained with a mean of 1.270.4% in the CD69 neg pool and with a mean of 2.372.0% in the CD69 low subset, respectively (Table 1) . To evaluate the residual alloreactivity of these cells, the proliferative response of both subsets against primary stimulator PBMC (first party) was compared with the original donor T cell population. As demonstrated for a representative experiment (Figure 2a) , the CD69 neg subset demonstrated a substantial decrease of alloresponses to the first-party stimulators with a mean residual alloreactivity of 1.670.5% as compared to the proliferative capacity of the original T cell population prior to depletion (100%) in all donor-recipient pairs tested. In contrast, the CD69 low subset showed significant persisting alloreactivity (25.374.7% mean value of all donors tested), supporting our finding of an additional subset composed of CD69 low T cells which retain the potential to exert alloreactivity.
In order to evaluate the specificity of allodepletion, we subsequently tested the proliferative capacity of the CD69 neg and CD69 low subsets against irrelevant HLA antigens expressed by allogeneic third-party targets. As shown for a representative experiment in Figure 2b , stimulation of CD69 neg as well as CD69 low T cells in secondary MLC with third-party PBMC completely HLA-mismatched to the first-party stimulators revealed a comparable preservation of anti third-party target responses in both subsets when compared to alloreactivity exerted by original T cells prior to depletion. In summary, these data suggest that alloreactivity can be efficiently and specifically eliminated using a stringent CD69-based depletion strategy.
CMV and EBV-specific CD8
þ T lymphocytes are retained after depletion of anti-MHC mismatch responders Recurrent viral infections predominantly caused by CMV and EBV remain major complications in patients after AHSCT. Hence, we examined the retainment of antiviral T cell specificities after CD69-mediated allodepletion using IFN-g ELISpot assays. PBMC of HLA-A*0201-positive healthy donors previously infected with CMV and EBV were initially screened for memory CD8 þ T cells recognizing HLA-A*0201-restricted peptide epitopes of CMV pp65 and EBV BMLF1 proteins, respectively. Subsequently, T cells isolated from donors with detectable antiviral reactivity were subjected to allogeneic stimulation with irradiated PBMC obtained from individuals without previous CMV and EBV exposure. After CD69-based depletion of alloreactive responders, T lymphocytes from the CD69 neg and the CD69 low subsets were stimulated with K562-HLA-A*0201 transfectants pulsed with the pp65 and BMLF1 peptides. Residual frequencies of antiviral T cells were compared with frequencies determined in T cells prior to the depletion maneuver.
As demonstrated in a total of three MHC-mismatched donor-recipient pairs and shown for one representative experiment in Figure 3a , CMV pp65/HLA-A2-reactive T cells persisted in the CD69 neg subset with a mean frequency of 70.5719.3% (range, 54.0-97.5%) when compared to the frequency of pp65-specific T cells detectable prior to the depletion procedure. Additionally, despite the absence of any known source of CMV antigen in the seronegative recipient PBMC, pp65-specific responders could be detected among retained allogeneic T cells expressing low amounts of CD69 at a mean frequency of 64.0714.0% (range, 49.0-83.0%). Similarly, EBV BMLF1-reactive T cells were also visualized within both the CD69 neg and CD69 low subsets of allogeneic T lymphocytes in all MHC-mismatched donor/recipient pairs analyzed (n ¼ 3) (Figure 3b) . Particularly, EBV reactivity was detectable at a mean frequency of 35.0719.0% (range, 8.3-53.8%) in the CD69 neg fraction as compared with untouched T cells. In addition, EBV-reactive T cells occurred within the CD69 low subset at frequencies comparable to predepletion levels. Although these observations may be explained by nonspecific trapping of T cells during the separation procedure, our results also suggest that a subset of virus-specific memory T cells persisting in these MLC might maintain low levels of CD69 expression, or acquire it due to bystander activity to levels sufficient for retaining these cells in the pool of alloreactive responders.
WT1-specific CD8
þ T cells persist after selective depletion of alloreactivity In addition to antiviral T cells, we further analyzed allodepleted T lymphocytes for specificities potentially mediating GVL responses. Since cytotoxic T lymphocytes (CTL) specific for the HLA-A*0201-binding peptide 126-134 encoded by the leukemia-associated WT1 antigen can be detected at low frequencies in PBMC of healthy donors, 24 we tested whether WT1 peptide-specific T cells are retained after CD69-based depletion of anti-MHCmismatch responders. Purified CD3 þ T cells from HLA-A2-positive donors with anti-WT1 reactivity were subjected to MHC-mismatch MLC followed by allodepletion via CD69. Since K562-HLA-A*0201 transfectants present endogenously processed WT1 and thus elicit strong background reactivity, 25 HLA-A*0201-expressing TAP-deficient T2 cells were used as APC.
Significant WT1 reactivity above background levels was demonstrated in the CD69 neg subset with a frequency of 54.376.0% of specific T cells detected prior to the depletion procedure (Figure 4 ). This response determined by ELISpot analysis was specific for the HLA-A*0201-binding WT1 peptide since no significant reactivity above background was detectable in the presence of the irrelevant WT1 301-310 nonamer presented by HLA-A*2402 ( Figure 4 present before depletion or induced due to bystander activation.
CD4
þ CD25 þ regulatory T cells do not upregulate CD69 after allostimulation As recent studies suggest that CD4 þ CD25 þ regulatory T cells play an important role in the suppression of GVH reactions, 21, 26 persistence of this cell type in manipulated stem cell allografts and DLI appears desirable. CD4 þ CD25 þ T cells isolated from healthy blood donors have been described to be CD69 negative, although upregulation of CD69 expression on CD4 þ CD25 þ T cells after CD3-mediated polyclonal T cell stimulation has been observed. 27, 28 Since CD4 þ CD25 þ T reg cells constitutively express Foxp3, 29 we examined the expression level of CD69 on CD4
þ Foxp3 þ T reg cells prior to and after allogeneic stimulation.
Among fresh PBMC isolated from buffy coat preparations and stained for T cells expressing CD4, CD25, CD69 and Foxp3, 4.5% of all CD4 þ T cells were positive for Foxp3 (Figure 5a ). This subset of CD4 þ Foxp3 þ T cells coexpressed CD25 (data not shown). In contrast, these T reg cells did not express any CD69 (Figure 5a ). As expected, a small population of CD4 þ T cells showed expression of CD25 and CD69 probably reflecting preactivated conventional T cells commonly present in PBMC obtained from buffy coat preparations. Following allostimulation for 3 days, MLC responder cells were analyzed for expression of CD69, CD25 and Foxp3 (Figure 5b) . Whereas, the number of CD69
þ T cells increased in allogeneic MLC, the number of Foxp3 þ cells within allostimulated CD4 þ T cells remained comparable to the original population (5.1% versus 4.5%, Figure 5b) . Moreover, CD69-expressing activated T cells were largely negative for Foxp3, suggesting that Foxp3 expression was restricted to CD4 þ CD69 À T reg cells (Figure 5b ). This result was confirmed following separation of alloreactive responder cells and analysis of the CD69 neg subset as again a small proportion of CD4 þ T cells (4.3%) comparable to the original CD4 þ population (4.5%) maintained Foxp3 expression but was virtually absent of CD69 (Figure 5c ).
In summary, our data suggest that donor-derived CD4 þ CD25 þ Foxp3 þ T reg cells do not upregulate CD69 upon allogeneic stimulation, and, therefore, should persist among allodepleted donor T lymphocytes.
Discussion
Several different strategies to selectively inhibit or deplete alloreactivity by costimulatory blockade, 30 by photodynamic purging, 12 by AICD, 7 or by CD25-immunotoxinmediated killing [14] [15] [16] [17] have been developed. However, elimination of alloreactive T cells via CD25 may also affect CD4 þ CD25 þ regulatory T cells increasingly being recognized as suppressors of alloreactivity. 21, 26 In contrast, selective allodepletion via CD69 appears to be an attractive approach since CD69 represents an antigen that is very early and transiently expressed on T cells upon activation. 31 Based on published previous work, 18, 19 we explored a modified CD69-mediated immunomagnetic cell separation protocol to selectively deplete alloreactive T cells ex vivo from the total pool of donor lymphocytes. Following stimulation of TCD with MHC-mismatched recipient PBMC in bulk MLC, activated alloreactive CD69 pos responders could be depleted with a mean efficiency of X95%. Additional separation of the supposedly nonalloreactive cells passing through the column within the first and second effluent fractions revealed a subset of truly CD69 neg cells and a population of allogeneic T lymphocytes expressing low amounts of CD69. While T cells present in the CD69 neg subset did not evoke any detectable alloresponses to the first-party stimulators, significant (i.e. 25%) residual alloreactivity was observed in the population of CD69 low -expressing T cells. These in vitro results could be further confirmed in a murine MHC-mismatched P-F 1 GVHD model where the adoptive transfer of CD69 low but not CD69 neg cells could reproducibly induce GVHD in sublethally irradiated recipient mice (data not shown). Accordingly, in the human setting the CD69 low subset should not be included to specific DLI products administered in adoptive immunotherapy studies.
Upon restimulation with irrelevant third-party allogeneic stimulators, T cells from both the CD69 neg and CD69 low subsets still exhibited significant anti third-party responses to comparable levels obtained with the original T cell population prior to separation. This suggests that the depletion of CD69 pos alloreactive T lymphocytes is specific for a given alloantigen and, thereby, confirms previously reported results. 18 In addition, similar experiments performed in the murine system demonstrated that MHCmatched hemagglutinin-specific T cells added to allogeneic MLC could be retrieved following allodepletion via CD69 (data not shown) further strengthening our findings.
Aside from severe GVHD, opportunistic infections, particularly caused by CMV and, albeit less frequently, by EBV remain major causes of morbidity and mortality after AHSCT. 32 Both CD8 þ CTL as well as CD4 þ T helper cells have been shown to play a central role in controlling CMV and EBV infections. 32 In the study presented herein, we demonstrated in HLA-A*0201-matched donor-recipient pairs that antiviral CD8 þ T lymphocytes are preserved in the CD69 neg subset at reduced but still significant levels. Similarly, as allogeneic T lymphocytes are pivotal mediators of GVL responses, 33 we examined the retainment of HLA-A*0201-restricted, WT1 peptide-specific T cells in healthy donors with detectable WT1 reactivity. 34 Using TAP-deficient T2 cells devoid of endogenous WT1 presentation we showed that WT1-specific T cells can be observed in the CD69 neg subset after CD69-mediated allodepletion with somewhat reduced frequencies but still significant levels compared to original unmanipulated donor PBMC. To our knowledge, this is the first report demonstrating that WT1-specific T cells potentially bearing GVL reactivity can be retained among allogeneic T lymphocytes following allodepletion ex vivo. Moreover, our findings extend recently published data on the preservation of donor-derived CTL recognizing the PR1 epitope from proteinase 3 expressed in acute and chronic myeloid leukemia following allodepletion. 16 The partial loss of allogeneic T lymphocytes with specificities to immunodominant viral or leukemia-associated epitopes found in the CD69 low subset may partly reflect nonspecific trapping prior to the subsequent washing steps. However, as T lymphocytes derived from healthy donors with reactivities to CMV, EBV and WT1, respectively, most likely represent memory-type T cells they might express residual amounts of CD69. 35 This CD69 expression could be sufficient to allow for their capture within the population of CD69 low cells still mediating significant alloreactivity. Indeed, CMV-reactive T cells have recently been reported to disproportionately express CD69 in vivo in healthy seropositive donors over extended time periods, indicating that recurrent restimulation of CMV-responsive effector cells occurs to maintain antiviral immunity. 35 Alternatively, although MLC were performed with stimulator cells tested negative for CMV, EBV and WT1 immunity, we cannot completely exclude the possibility that the relevant donor specificities might have experienced 'bystander' activation during repetitive stimulation of alloreactive responders resulting in low CD69 expression. Noteworthy, the finding that high frequencies of CD69-expressing BMLF1-specific T cells could be detected in synovial fluids of autoimmune rheumatoid arthritis patients in the absence of BMLF1 in the joint 36 supports this possibility.
Finally, we investigated the persistence of T reg cells after allogeneic stimulation using flow cytometry to determine expression levels of Foxp3 in combination with the T reg markers CD4 and CD25. While several distinct phenotypes of regulatory T cells are being discussed, CD4 þ T cells which coexpress CD25 are widely accepted to define for cells with regulatory activity. 37, 38 Furthermore, expression of Foxp3 appears to represent an additional and reliable marker for identifying T reg cells. Among freshly isolated PBMC about 4.5-5.0% of CD4 þ T cells expressed Foxp3 but no detectable levels of CD69. After stimulation in allogeneic MLC, this population of CD4 þ Foxp3 þ T cells did not show any signs of proliferation when compared to the original population prior allostimulation. Most importantly, these cells remained CD69 negative, strongly suggesting that CD4 þ CD25 þ regulatory T lymphocytes do not upregulate CD69 expression upon encountering allogeneic stimulator cells in vitro and thus should not be affected by the CD69-mediated allodepletion strategy.
In conclusion, our results demonstrate that the CD69-mediated removal of alloreactive T cells is a feasible strategy to achieve very efficient allodepletion from donor lymphocyte products ex vivo while retaining beneficial antiviral, antileukemic and regulatory T cell functions. In addition, the data presented in this study confirm previous work on CD69-mediated allodepletion 18, 19, 39 and extend these findings to the persistence of WT1-specific T cells after the depletion procedure. The strong residual alloreactivity against first-party stimulators observed in the CD69 low subset certainly prevents the inclusion of this cell population in a specific DLI product to be used for adoptive cell therapy studies in humans. Therefore, efforts are currently in progress to amplify retained antiviral and antileukemic T cell specificities in the CD69 neg subset in vitro, for example by the use of immobilized anti-CD3 and -CD28 monoclonal Abs successfully used for the expansion of CMV-specific T cells. 40 Since it appears feasible to expand even low numbers of antigen-specific T lymphocytes to amounts sufficient for adoptive immunotherapy as recently shown for CMV-specific T cells, 41 our results might be useful for the generation of allodepleted DLI products to be administered after AHSCT.
